Top Page
Singular Health Group Ltd
(Sydney:SHG)
Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)
Singular Health Group Ltd Business Overview & Revenue Model
Singular Health Group Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 75.37K | 90.83K | 616.14K | 54.03K | 193.64K | 103.86K | Gross Profit |
| -274.44K | -2.67M | -3.58M | -2.11M | -1.62M | -669.39K | EBIT |
| -2.10M | -3.93M | -5.09M | -5.97M | -2.99M | -669.39K | EBITDA |
| -1.76M | -2.89M | -4.52M | -5.72M | -2.90M | -637.00K | Net Income Common Stockholders |
| -1.92M | -4.92M | -5.39M | -5.99M | -4.46M | -707.59K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.63M | 1.45M | 691.51K | 1.14M | 4.14M | 130.55K | Total Assets |
| 5.11M | 2.35M | 3.00M | 2.14M | 5.43M | 668.27K | Total Debt |
| 0.00 | 218.45K | 2.51M | 85.66K | 147.59K | 745.94K | Net Debt |
| -4.63M | -1.23M | 1.82M | -1.05M | -3.99M | 615.39K | Total Liabilities |
| 311.99K | 909.59K | 2.94M | 391.50K | 345.10K | 881.86K | Stockholders Equity |
| 4.80M | 1.44M | 61.89K | 1.75M | 5.08M | -213.59K |
| Cash Flow | Free Cash Flow | ||||
| -1.22M | -2.51M | -2.49M | -2.92M | -2.22M | -807.48K | Operating Cash Flow |
| -1.22M | -2.44M | -2.46M | -2.91M | -1.91M | -548.17K | Investing Cash Flow |
| 43.14K | -3.56K | -635.21K | -17.12K | -610.57K | -259.31K | Financing Cash Flow |
| 4.35M | 3.21M | 2.65M | -69.25K | 6.52M | 950.69K |
Singular Health Group Ltd Technical Analysis
Singular Health Group Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$17.93M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
55 Neutral | AU$84.73M | ― | -457.46% | ― | 21.93% | 10.34% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
50 Neutral | AU$81.64M | ― | ― | ― | ― | ||
39 Underperform | $23.37M | ― | -130.18% | ― | 3.37% | 47.32% | |
27 Underperform | AU$1.28M | ― | -147.32% | ― | ― | 26.09% |
Singular Health Group Ltd Corporate Events
Singular Health Group Ltd has issued 844,985 fully paid ordinary shares following the exercise of unlisted options, raising $86,988.50. This move reflects the company’s ongoing compliance with the Corporations Act and its strategic efforts to enhance its financial position, potentially impacting its market operations and stakeholder interests.
Singular Health Group Ltd has announced the quotation of 844,985 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move follows the exercise of options or conversion of other convertible securities, reflecting the company’s ongoing financial activities and potential growth strategy. The announcement signifies an expansion in the company’s market presence and could have implications for its stakeholders by potentially increasing liquidity and shareholder value.
Singular Health Group Ltd has announced a change in the director’s interest, with Howard Digby acquiring 1,000,000 unlisted options as part of his non-executive director remuneration package. This allotment, approved by shareholders, reflects the company’s commitment to aligning its leadership incentives with long-term strategic goals, potentially impacting its market positioning and stakeholder confidence.
Singular Health Group Ltd has announced the issuance of 1,030,000 fully paid ordinary shares following the exercise of unlisted options, raising $154,500. This move demonstrates the company’s ongoing efforts to strengthen its financial position and potentially expand its operations. The announcement, authorized by the Board of Directors, indicates compliance with relevant sections of the Corporations Act, ensuring transparency and adherence to regulatory standards. This development could have positive implications for the company’s market presence and stakeholder confidence.
Singular Health Group Ltd has announced the issuance of 1,030,000 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code SHG. This move is part of the company’s strategy to leverage convertible securities and options, potentially strengthening its financial position and enhancing its market presence.
Singular Health Group Ltd has successfully completed several strategic and technical milestones in the March 2025 quarter, including the completion of a technical proof of concept with Provider Network Solutions (PNS) and the development of the 3Dicom Gateway. These achievements have accelerated the company’s progression to a commercial pilot phase with PNS, strengthening their relationship and positioning Singular Health for commercialization opportunities in the U.S. The company has also secured over $965k in funding, enhancing its financial position and readiness for the upcoming U.S. pilot program. Additionally, Singular Health has engaged with investors through targeted roadshows, attracting interest from institutional investors and reinforcing its commitment to improving medical imaging accessibility.
Singular Health Group Ltd has announced the issuance of unquoted equity securities, specifically unlisted options with varying expiration dates in 2028 and 2029. This strategic move is part of a previously announced transaction, potentially impacting the company’s financial structure and offering stakeholders insights into its long-term operational strategies.
Singular Health Group Ltd announced the release of 200,000 fully paid ordinary shares from voluntary escrow, effective 28 March 2025. This release does not alter the company’s issued capital, indicating a stable financial position. The move could enhance liquidity and investor confidence without impacting the company’s capital structure.
Singular Health Group Ltd has successfully completed a capital raising initiative by issuing 5,555,556 new shares at $0.09 each, raising $500,000, with Provider Network Solutions as a cornerstone investor. This strategic move, approved by shareholders, is expected to bolster Singular Health’s financial position and enhance its market presence in the medical technology industry.
Singular Health Group Ltd has announced the quotation of 5,555,556 ordinary fully paid securities on the ASX, as part of a previously announced transaction. This move is expected to enhance the company’s financial position and potentially increase its market presence, benefiting stakeholders by providing increased liquidity and investment opportunities.
Singular Health Group Ltd has announced the quotation of 50,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of March 27, 2025. This move indicates the company’s strategic efforts to enhance its market presence and potentially increase liquidity for its stakeholders.
Singular Health Group Ltd announced that all resolutions at their recent General Meeting were carried via a poll. This includes the ratification of placement shares and the issuance of options to directors, which reflects strong shareholder support and could enhance the company’s strategic initiatives and market positioning.
Singular Health Group Ltd reported a significant decline in revenue for the half-year ending December 2024, with a 90% drop compared to the previous year. The company also experienced a 69% increase in net losses, attributed to discontinued operations and the loss of control over Singular 3DP Pty Ltd. Despite these challenges, the net tangible assets per ordinary security improved from 0.68 to 1.92 cents, indicating some positive movement in asset management.